Mirum Pharmaceuticals (MIRM) Accounts Payables (2018 - 2026)

Mirum Pharmaceuticals' Accounts Payables history runs 9 years deep, the most recent figure standing at $59.4 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 410.34% year-over-year to $59.4 million; the TTM figure through Mar 2026 stood at $59.4 million (up 410.34% YoY), while the FY2025 annual figure was $9.6 million, down 34.23% from the prior year.
• Accounts Payables for Q1 2026 stood at $59.4 million, up from $9.6 million in the prior quarter.
• The five-year high for Accounts Payables was $59.4 million in Q1 2026, with the low at $4.9 million in Q1 2022.
• The 5-year median for Accounts Payables is $9.8 million (2024), against an average of $13.4 million.
• The sharpest annual moves came in 2025 and 2026: Accounts Payables slumped 34.23% in 2025, then surged 410.34% in 2026.
• Mirum Pharmaceuticals' Accounts Payables stood at $8.7 million in 2022, then declined by 14.66% to $7.4 million in 2023, then jumped by 97.11% to $14.6 million in 2024, then plunged by 34.23% to $9.6 million in 2025, then soared by 517.84% to $59.4 million in 2026.
• Business Quant data shows MIRM's Accounts Payables at $59.4 million in Q1 2026, $9.6 million in Q4 2025, and $12.2 million in Q3 2025.